YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* Pharming press release [https://seekingalpha.com/pr/20434204-pharming-group-reports-fourth-quarter-and-full-year-2025-financial-results-delivering-strong] (PHAR [https://seekingalpha.com/symbol/PHAR]): Q4 GAAP EPS of $0.01 in-line. * Rev…
Pharming Group logo Key Points 2026 guidance above Street: Pharming forecasted revenue of $405–$425 million for 2026 (8–13% growth vs. 2025), beating an analyst consensus of about $398 million, with an implied ~90% gross margin and operati…
The European markets have recently faced a downturn, with the pan-European STOXX Europe 600 Index and major national indices like France’s CAC 40 and Germany’s DAX experiencing declines amid renewed trade and geopolitical uncertainties. De…
As the pan-European STOXX Europe 600 Index edges closer to record highs, optimism about future earnings and economic prospects is creating a favorable backdrop for investors. Penny stocks, although an outdated term, continue to capture att…
Amidst renewed concerns over inflated AI stock valuations, European markets have experienced a downturn, with the pan-European STOXX Europe 600 Index declining by 2.21%. Despite these broader market challenges, investors continue to explor…
The European markets have shown resilience with the pan-European STOXX Europe 600 Index climbing 1.68% and major stock indexes across the continent experiencing gains, reflecting a robust economic outlook bolstered by strong business activ…
Pharming Group N.V. Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small Cap) to the AMX® (M…
* Pharming Group (PHAR [https://seekingalpha.com/symbol/PHAR]) appointed [https://seekingalpha.com/pr/20216757-pharming-group-appoints-kenneth-lynard-as-chief-financial-officer] Kenneth Lynard as CFO, effective October 1, 2025. * Mr. Lynar…
The European market has recently seen a boost, with the pan-European STOXX Europe 600 Index climbing 1.18% amid easing trade tensions and optimism about U.S. interest rate cuts, contributing to positive sentiment across major indices like…
* Pharming Group N.V. press release [https://seekingalpha.com/pr/20184004-pharming-group-reports-second-quarter-and-first-half-2025-financial-results-and-provides] (OTCPK:PHGUF [https://seekingalpha.com/symbol/PHGUF]): Q2 GAAP EPS of $0.00…
As Europe navigates a landscape marked by tentative optimism surrounding an EU-U.S. trade deal and the European Central Bank's steady interest rates, the pan-European STOXX Europe 600 Index has seen modest gains, reflecting a cautious yet…
The European market has recently experienced significant declines, with the pan-European STOXX Europe 600 Index dropping 8.44% amid heightened trade tensions and economic uncertainty stemming from new U.S. tariffs. In this challenging envi…
Pharming Group N.V. Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance Expect Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year end Leiden, The Netherlands, January 8, 2024…
Pharming Group N.V. Initial development in PIDs with immune dysregulation linked to PI3Kẟ signaling Phase 2 clinical trial initiation planned for2Q 2024 Leiden, The Netherlands, December 13, 2023: Pharming Group N.V. (“Pharming” or “the Co…
Pharming Group N.V. The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The Netherlands, November 21, 2023: P…
Pharming Group N.V. Leiden, The Netherlands, November 10, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has received a Day 180 Second List of Outstanding Issues (LoOI) fr…
Pharming Group N.V. Leiden, The Netherlands, November 7, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces 14 poster presentations by the Company or its collaborators regarding lenio…
Pharming Group N.V. Leiden, The Netherlands, November 1, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the mon…
Pharming Group N.V. Pharming Group reports third quarter 2023 financial results Third quarter 2023 revenues increased 23% to US$66.7 million, compared to the third quarter 2022, driven by RUCONEST® revenue and the U.S. commercial launch of…
iTeos Therapeutics, Inc. ITOS shares ended the last trading session 5.4% higher at $9.04. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 30.1% l…
Pharming Group N.V. Leiden, The Netherlands, October 12, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2023 financial results, for the peri…
Leiden, The Netherlands, September 25, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM…
Pharming Group N.V. Sponsored ADR (PHAR) shares rallied 14.7% in the last trading session to close at $15.98. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compa…
LEIDEN, The Netherlands, Aug. 24, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences in the U.S. in the…
LEIDEN, The Netherlands, Aug. 14, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM/Nasdaq: PHAR) announces it will hold an Extraordinary General Meeting of Shareholders (EGM) on Monday, September 25,…
Single-arm Phase III study in Japan evaluating leniolisib in patients aged 12 years and older with APDS, a rare primary immunodeficiency LEIDEN, The Netherlands, Aug. 9, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company"…
RUCONEST® business performed strongly in 2Q 2023; continue to anticipate low single digit annual revenue growth Strong start to U.S. Joenja® launch during 2Q 2023; 43 patients on paid therapy and US$3.8 million revenue 1H 2023 revenues inc…
LEIDEN, The Netherlands, July 18, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has nominated Dr. Richard Peters to become Pharmi…
LEIDEN, The Netherlands, July 13, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2023 financial results, for…
LEIDEN, The Netherlands, June 1, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has entered into a definitive agreement with Novartis Pharma A.G. ("Novartis…
LEIDEN, The Netherlands, May 25, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will attend the following investor conferences in the month of June: Pharm…
LEIDEN, The Netherlands, May 17, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, the proposal for a specif…
FDA approval and commercial launch of Joenja® (leniolisib) in the U.S. Joenja® launch off to strong start with 23 U.S. patients on paid therapy Revenues decreased by 9% to US$42.5 million, compared to the first quarter of 2022, primarily d…
It hasn't been the best quarter for Pharming Group N.V. (AMS:PHARM) shareholders, since the share price has fallen 14% in that time. While that might be a setback, it doesn't negate the nice returns received over the last twelve months. To…
LEIDEN, Netherlands, April 26, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces that Pharming's Chief Executive Officer, Sijmen de Vries will attend the H.C. Wainwright BioConnect I…
Pharming Group N.V. Sponsored ADR PHAR shares ended the last trading session 5.2% higher at $10.94. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock…